Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 4 days ago

MACROGENICS INC: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Armistice Capital, LLC amended its Schedule 13G stake filing for MacroGenics Inc., disclosing the change to the SEC under accession number 0001172661-26-005245. The filing updates the investment firm's reported position in the clinical-stage biopharmaceutical company, though the headline disclosure did not specify the revised share count or percentage. Schedule 13G amendments are typically filed by passive investors and are closely watched for signals about institutional conviction in small-cap biotech names. Investors will look to the full filing for Armistice's updated ownership percentage and any change in shares held.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Armistice Capital, LLC, MacroGenics Inc